Leerink Partners now expects Eli Lilly's (LLY) Foundayo in diabetes to be approved in 2H26
Leerink Partners analyst David Risinger reiterated an Outperform rating and $1,296.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)